嘉宾： 董事长 罗总 副总经理 区总 01 主题： 蜂助手定增布局AI端侧和芯片交流 时间： 10月12日（周日）20:00 董秘 韦总 主持：曹佩 计算机首席分析师 参会密码：442996 02 主 题： 生命科学上游行业深度报告 参会密码：373505 03 主 题： 行业配置模型回顾与更新系列（十三） 时间： 10月13日（周一）21 : 00 主讲：刘晓锋 金工首席分析师 参会密码：114207 04 主题：天秦装备深度报告 时间： 10月14日（周二）17 : 00 主讲： 马浩然 军工分析师 参会密码：384300 05 主题： 有色行业周观点更新 时间：10月15日（周三）19 : 00 主讲：张文臣 有色及新材料首席分析师 时间： 10月13日（周一）16 : 00 主讲：谭紫媚 医药首席分析师 参会密码： 723044 06 主题：兴业银行中报解读及投资价值分析 时间： 10月16日（周四）14 : 00 主讲： 夏芈卬 金融行业首席分析师 参会密码：917551 07 主题： 医药行业观点及华领医药更新推荐 时间：10月16日（周四）15 : 00 主讲： 周豫 医药首席分析师 戎晓婕 医 ...

10月10日， 2025年《财富》可持续发展峰会在福州成功举办。 峰会以"智能时代，智惠共生"为主题，汇集近200位全球工商界的可持续发展践行者、政策制定者与学术专家，共同探寻科技赋能下的可持续发展路径， 确保技术进步能够带来人类福祉的"净增长"。 来自AI、互联网、制造、新能源、金融、健康等领域的40位发言嘉宾通过分享真实案例与深度思考，探讨了多个关键议题：智能技术如何在为增长提速 的同时，避免对环境的过度消耗？跨国企业如何在日益割裂的地缘与市场格局中，秉持社会责任与多元文化？在算法日益主导的时代，如何保障人类的创 造力与发展权？ 以下为2025年《财富》世界500强峰会的精彩观点。 但同时也需要来自社会多方面的 利益相关者加入,要从前端着手, 并设有相应的法规驱动和激励 制度。99 余 怪 霍尼韦尔 大中华区总裁 66 供应商如果产品质量好、交货好, 同时符合 ESG 标准,将获得更多 订单和来自全球的机会。中国 供应商在质量、成本、交货方面 很'卷',且ESG 做得很好, 期待更多订单落地中国。99 楼 翔 福建永荣控股集团 副董事长 66 对化工企业而言,绿色低碳转型 是非常迫切的使命。既有助于 实现 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 1,056,213,761 | | 0 | | 1,056,213,761 | | 增加 / 減少 (-) | | | 391,255 | | 0 | | | | 本月底結存 | | | 1,056,605,016 | | 0 | | 1,056,605,016 | 第 2 頁 共 10 頁 v 1.1.1 III.已發行股份及/或庫存股份變動詳情 | 截至月份: | 2025年9月30日 | | | | 狀態: 新提交 | | --- | --- | --- | - ...

本报讯 （记者金婉霞）9月29日，华领医药宣布，中国香港特别行政区卫生署已正式受理多格列艾汀 （dorzagliatin）的新药上市许可申请（NDA）。 华领医药方面认为，此次NDA被受理是华领医药拓展中国大陆以外市场战略的一个重要里程碑，有望 将其创新的疾病疗法带给更多亚洲患者，并最终推向全球市场。"香港有超过50万人患有糖尿病，亚洲 有近2.4亿人患有糖尿病，多格列艾汀的NDA是解决该地区最紧迫的健康挑战之一的重要一步。"华领医 药在官方微信号中表示。 据悉，香港在新药审批制度规定中新设了"1+"机制下，在符合本地临床数据支持等要求，并经本地专家 认可新药的适用范围后，只须提交一个（而非原来的两个）参考药物监管机构的许可，便可以在香港申 请注册。该制度最早适用于治疗严重或罕见疾病的新药，2024年开始扩展至所有新药。华领医药积极与 香港当地临床专家和监管部门进行了充分且深入的沟通，成为这一政策的早期探路者。 截至目前，多格列艾汀已于2022年9月份在中国大陆获批，并被纳入于2024年1月1日正式执行的国家医 保药品目录。其获批适应症为：单独用药治疗未经药物治疗的2型糖尿病患者，可以用于一线治疗；在 单独使 ...

Core Insights - Hualing Pharmaceutical's drug Huatangning, the world's first glucose kinase activator (GKA) for diabetes, was approved in 2022, marking a significant milestone in China's biopharmaceutical industry [1][4] - Despite initial expectations, Huatangning's sales performance was underwhelming while partnered with Bayer, leading to a strategic shift to self-commercialization in 2025, resulting in a significant sales increase [1][8][15] - The drug's development faced challenges, with previous GKA candidates failing due to a lack of understanding of glucose kinase's role as a blood sugar sensor, which Hualing addressed by focusing on blood sugar variability rather than just lowering blood sugar levels [5][6][9] Company Performance - After taking back commercialization rights from Bayer, Hualing Pharmaceutical's sales team expanded significantly, achieving a 108% year-on-year increase in Huatangning's sales volume to 1.764 million boxes in the first half of 2025 [15] - The company reported a revenue of 2.174 billion yuan from Huatangning, with a net profit of 11.839 billion yuan, largely due to a one-time payment from terminating the agreement with Bayer [15][16] - Hualing's performance is part of a broader trend in the Chinese innovative drug sector, which saw a 7.26% revenue growth among 84 innovative drug companies in the first half of 2025 [15] Industry Trends - The Chinese innovative drug market is experiencing a surge, with domestic drugs accounting for 38% of global new drug approvals in 2024, expected to exceed 50% in 2025 [17] - The ongoing business development (BD) trend indicates a growing alignment between domestic biotech companies and international pharmaceutical firms, with a significant portion of FDA-approved drugs originating from biotech [17][18] - Future opportunities in the biotech sector are anticipated as new modalities like ADCs and bispecific antibodies emerge, suggesting that the market for innovative drugs will continue to expand [18]

Core Insights - Hualing Pharmaceutical's drug Huatangning, the world's first glucose kinase activator (GKA) for diabetes, was approved in 2022, marking a significant milestone in China's biopharmaceutical industry [2] - Despite initial expectations, Huatangning's sales performance was underwhelming while partnered with Bayer, leading to a strategic shift to self-commercialization in 2025, resulting in a sales volume increase of 108% in the first half of 2025 [2][14] - The company emphasizes the importance of glucose kinase's "glucose-dependence" in its drug development, aiming to stabilize blood sugar levels rather than merely lowering them [5][8] Company Development - Huatangning's development began in 1995, inspired by the discovery of glucose kinase, which regulates blood sugar levels [3][4] - The drug faced significant challenges, with over 20 candidates failing before Huatangning's success, attributed to a misunderstanding of glucose kinase's role [5] - The drug's clinical trials showed a low incidence of hypoglycemia, maintaining below 1% during trials and post-market surveillance [6] Commercial Strategy - Initially, Hualing partnered with Bayer for commercialization, which included a prepayment of 300 million yuan and potential milestone payments up to 4.18 billion yuan [7] - The partnership was seen as a model for collaboration between domestic biotech firms and multinational pharmaceutical companies, leveraging Bayer's market presence [7][12] - However, Bayer's internal restructuring and management inefficiencies hindered the drug's market performance, prompting Hualing to take over commercialization [12] Financial Performance - After taking back commercialization rights, Hualing's sales team expanded significantly, achieving a sales volume of 1.764 million boxes in the first half of 2025, with revenue reaching 217.4 million yuan [14] - The company reported a one-time income of 1.2435 billion yuan from terminating the agreement with Bayer, leading to a net profit of 1.1839 billion yuan, marking its first profitable quarter since going public [14] Industry Trends - The Chinese innovative drug market is experiencing rapid growth, with domestic drugs accounting for 38% of global new drug approvals in 2024, projected to exceed 50% [15][16] - The surge in interest in innovative drugs is linked to improved R&D efficiency and a growing trend of business development (BD) collaborations between biotech firms and multinational companies [15][16] - Future opportunities in the biotech sector are expected to arise from new modalities and technologies, indicating a continuous demand for innovative drug development [17]

HUA MEDICINE 華領醫藥 (Incorporated in Bermuda with limited liability) （於百慕達註冊成立之有限公司） (Stock code 股份代號： 2552) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Non-registered Holder(s)(Note 1), Hua Medicine (the "Company") – Notice of publication of Interim Report 2025 (the "Current Corporate Communication") The English and Chinese versions of the Company's Current Corporate Communications are available on the Company's website at www.huamedicine.com and the website of The Stock Exchange of Hong Kong Limited (th ...

（於百慕達註冊成立之有限公司） (Stock code 股份代號： 2552) NOTIFICATION LETTER 通知信函 26 September 2025 Dear Registered Shareholders, HUA MEDICINE 華領醫藥 (Incorporated in Bermuda with limited liability) Actionable Corporate Communications refer to any corporate communications that seek instructions from the Shareholders on how they wish to exercise their rights or make elections as Shareholders. 各位登記股東： 華領醫藥（「本公司」） —中期報告2025（「本次公司通訊」）之刊發通知 Hua Medicine (the "Company") – Notice of publication of Interim Report 2025 (the "Current C ...

非執行董事 Hua Medicine 華領醫藥 ( 於開曼群島註冊成立的有限公司 ) 股份代號 : 2552 中期報告 2025 目錄 | 公司資料 | 2 | | --- | --- | | 業務與財務摘要 | 4 | | 管理層討論及分析 | 7 | | 簡明綜合財務報表審閱報告 | 27 | | 簡明綜合損益及其他全面收益表 | 28 | | 簡明綜合財務狀況表 | 29 | | 簡明綜合權益變動表 | 31 | | 簡明綜合現金流量表 | 32 | | 簡明綜合財務報表附註 | 34 | | 其他資料 | 51 | | 釋義 | 57 | 頁次 中期報告 2025 2 公司資料 執行董事 陳力 （首席執行官） 林潔誠 （執行副總裁及首席戰略官） 張怡 （首席醫學官） Robert Taylor NELSEN （主席） 獨立非執行董事 William Robert KELLER 徐耀華 張耀樑 審核委員會 張耀樑 （主席） William Robert KELLER 徐耀華 薪酬委員會 William Robert KELLER （主席） 徐耀華 提名委員會 Robert Taylor NELSEN （ ...

FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 截至月份: | 2025年8月31日 | | | | 狀態: 新提交 | | --- | --- | --- | --- | --- | --- | | 致：香港交易及結算所有限公司 | | | | | | | 公司名稱: | 華領醫藥 | | | | | | 呈交日期: | 2025年9月4日 | | | | | | I. 法定/註冊股本變動 | | | | | | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | 證券代號 (如上市) | 02552 | 說明 | 普通股 | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | --- | --- | --- | --- | --- | --- | --- | | 上月底結存 | | 2,000,000,000 | USD | 0.001 | USD | 2,000,000 | | ...